Targovax and Oncos Therapeutics are joining forces to create a Nordic leader in immuno-oncology and contemplate a private placement of NOK 125 to 150 million to fund combined business.
Creating Nordic leader in immuno oncology
Targovax and Oncos Therapeutics are joining forces to create a Nordic leader in immuno-oncology and contemplate a private placement of NOK 125 to 150 million to fund combined business.
Creating Nordic leader in immuno oncology